How to Verify Your Compounding Pharmacy Is Legitimate
Verifying a compounding pharmacy takes about 15 minutes and four steps: (1) confirm state board of pharmacy licensure through the relevant state’s pharmacy board database, (2) verify USP compliance through accreditation lookup, (3) check for FDA warning letters in the FDA’s enforcement database, and (4) ask your telehealth provider to disclose the partner pharmacy in writing.[1]
A reputable telehealth provider will give you this information transparently. If a provider refuses to disclose which pharmacy is preparing your medication, that is the strongest possible signal to switch providers. Our editor’s pick on pharmacy transparency in 2026 is HermanRx, which discloses partner pharmacy status on request.
Why this matters.
Following the FDA’s February 2026 enforcement action on compounded GLP-1 medications, the regulatory environment for compounding has become more active. Operators that were compliant under the shortage exception are not all compliant under current rules. Verifying your pharmacy’s status before continued use is a 15-minute check that prevents continuity-of-care issues if your provider’s pharmacy partner falls out of compliance.
The four-step verification process
Step 1: Confirm state board of pharmacy licensure
Every legitimate compounding pharmacy is licensed by the state board of pharmacy in the state where it operates. Many are also licensed in additional states where they ship medications. Verification is free and takes about 3 minutes.
- Identify the pharmacy preparing your medication. Your telehealth provider should be able to tell you the name, address, and license number on request.
- Find the relevant state board of pharmacy. The National Association of Boards of Pharmacy maintains a directory at nabp.pharmacy.
- Search the state board’s pharmacy license lookup. Most state boards have a free online database where you can verify licensure status by pharmacy name or license number.
- Confirm the license is active and in good standing. The lookup should show no suspensions, disciplinary actions, or operational restrictions.
Step 2: Verify USP compliance and accreditation
Compounding pharmacies must follow United States Pharmacopeial Convention (USP) standards — specifically USP <797> for sterile compounding (most injectables fall here) and USP <795> for non-sterile compounding.[2] State boards enforce these standards as part of licensure, but additional voluntary accreditation through the Pharmacy Compounding Accreditation Board (PCAB) is a meaningful trust signal.
- PCAB accreditation lookup. Visit achc.org (the parent organization) and search for PCAB-accredited pharmacies. PCAB accreditation indicates the pharmacy has voluntarily met standards above and beyond state licensure.
- State inspection records. Many state boards publish recent inspection reports for licensed pharmacies. Recent inspections with no significant findings are a good sign; recent inspections with major findings warrant follow-up questions.
Step 3: Check for FDA warning letters
The FDA publishes all warning letters issued to compounding pharmacies in a public database. Following the February 2026 enforcement action, multiple compounding pharmacies received warning letters specific to semaglutide and tirzepatide compounding practices.
- Visit fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters.
- Search by company name. Recent warning letters appear with the date and category.
- If your pharmacy appears, read the warning letter carefully. A warning letter is not necessarily disqualifying — many are resolved through corrective actions — but it is information you should have.
Step 4: Ask your telehealth provider for written disclosure
The most efficient step is to simply ask. A reputable telehealth provider should disclose, in writing or through their support portal:
- The name and address of the pharmacy preparing your medication
- The pharmacy’s state of licensure
- Whether the pharmacy operates as a 503A or 503B facility
- Any accreditations (PCAB or equivalent)
- The pharmacy’s response if a regulatory change affects your prescription
If a provider refuses to disclose this information, or gives evasive answers, that’s a meaningful signal to consider switching. Operators that are confident in their pharmacy partners disclose those partners transparently.
HermanRx — partner disclosure on request.
Discloses 503A partner pharmacy status, state licensure, and accreditation on patient request. Published transition plan for regulatory changes.
Red flags to watch for
Beyond the four-step verification, these patterns suggest you should investigate further or consider switching providers:
- Refusal to disclose the pharmacy. The single strongest red flag. A legitimate operator will always be willing to tell you which pharmacy is preparing your medication.
- International shipping origins. Compounded GLP-1, peptides, and hormones legitimately prepared for US patients are dispensed from US-licensed pharmacies. Packages from international addresses (particularly common for “research chemical” suppliers) are not legitimate compounded medications.
- Pharmacy not listed in any state board database. If you can’t find the pharmacy in any state’s licensure lookup, the operation is not a licensed US compounding pharmacy.
- No clinical justification in your intake. Reputable compounders require documented clinical need for compounded medication. If your telehealth provider’s intake never asked about clinical justification, that’s a sign of a non-compliant workflow.
- Pressure to buy in bulk or pre-pay annually. Legitimate compounding pharmacies prepare medications based on individual prescriptions filled in normal monthly quantities. High-pressure annual pre-purchase tactics are a warning sign.
- Drastically below-market pricing. If pricing is significantly below the market range for compounded medications, the operator may be cutting corners on pharmacy quality, clinical oversight, or both.
What to do if you find something concerning
If verification turns up something that worries you, the practical steps:
- Don’t stop the medication abruptly. Sudden discontinuation of GLP-1 medications can cause rapid weight regain; sudden discontinuation of TRT or other hormones can cause symptoms. Talk to a provider about a structured transition before stopping.
- Document what you found. Save screenshots of licensure lookups, warning letters, or non-disclosure responses. This is useful if you later need to file a complaint with your state pharmacy board.
- Request your medical records. Federal law and most state laws give you the right to access your own medical records, including the clinical justification for any prescription.
- Switch to a verified provider. Use the four-step verification process on the new provider’s pharmacy partner before transferring care.
- Consider filing a complaint. State pharmacy boards take complaints seriously and investigate operators that don’t meet licensure standards.
For patients prioritizing pharmacy transparency in 2026, HermanRx is our editor’s pick. The provider discloses 503A partner pharmacy status, state licensure, and accreditation when patients ask. Operators that disclose freely are the operators that have nothing to hide.
Verification is your right as a patient. A 15-minute check protects continuity of your prescription, your safety, and your peace of mind.
Frequently asked questions
How long does verification take?
About 15 minutes for all four steps if you have the pharmacy name to start. Most of the time is reading the state pharmacy board lookup and the FDA warning letter database. Step 4 (asking your provider) can be the fastest if your provider is transparent.
Is PCAB accreditation required?
No. PCAB accreditation is voluntary and additional to state licensure. Many fully compliant pharmacies are not PCAB-accredited. State licensure is the legal requirement; PCAB is a positive signal but not a deal-breaker.
What’s the difference between 503A and 503B?
503A pharmacies compound medications for individual patients based on individual prescriptions. 503B pharmacies (outsourcing facilities) prepare medications in bulk for distribution to healthcare facilities. The February 2026 FDA enforcement specifically affected 503B compounding of semaglutide; 503A patient-specific compounding remains available. For full context, see our companion piece on the compounded GLP-1 legal status.
How often is this article updated?
Reviewed quarterly. State pharmacy board databases and FDA warning letter databases are updated continuously by the relevant authorities; this guide tracks any meaningful changes to the verification process itself.
Sources & Citations
- National Association of Boards of Pharmacy. State pharmacy licensure directory. nabp.pharmacy
- United States Pharmacopeial Convention. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations.
- U.S. Food and Drug Administration. Warning Letters database. fda.gov
- Pharmacy Compounding Accreditation Board. PCAB accreditation directory. achc.org